I’m a big Formula 1 fan and thoroughly enjoyed the TV coverage of the Las Vegas Grand Prix over the weekend.

The event hit a bit of a snag in the opening practice session, but overcame the problem within a few hours to continue as previously organized.

The amount of planning and preparation work that went into running a Grand Prix along the Strip and around some of the famous sites has been incredible. (For instance, I was in Vegas in May and the road was being resurfaced then specifically for the race).

The reason I’m mentioning it is that worldwide revenues for Formula 1 were approximately 2.5 billion dollars in 2022.

While 2022 revenues for the global pharma industry were around 1.4 trillion dollars.

Which makes me wonder why our industry still has a major issue with patient recruitment, when a much smaller industry can successfully deliver something so complicated straight off the bat.

You may also like

Biotech C-suites Should keep Patient Recruitment in Mind from the Outset
In biotech, a strong C-suite isn’t just about job titles - it’s about covering every part of the journey from discovery to delivery. Including being prepared to tackle one of the biggest ...
Key C-suite Roles for Biotech Success - The Chief Patient Recruitment Officer (CPRO)
While biotech companies have built C-suites with scientific, medical, financial, operational, and business expertise, a critical function has remained conspicuously absent - addressing one ...
Key C-suite Roles for Biotech Success - The Chief Business Officer (CBO)
The Chief Business Officer leads external strategy - licensing deals, identifying pharma partnerships, and developing long-term growth planning and market positioning strategies that ...